Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.
Furopenem is a novel orally active penem. In this study, furopenem was highly active in vitro against Streptococcus pneumoniae (MIC90 0.03 mg/L), Haemophilus influenzae (MIC90, 2 mg/L), and Moraxella catarrhalls (MIC90, 0.5 mg/L). Its activity was not reduced by a variety of beta-lactamase enzymes, however beta -lactam resistance by other mechanisms was associated with higher MICs.
Cormican
M G
MG
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
Jones
R N
RN
D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology; D015780:Carbapenems / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000187:drug effects / Q000201:enzymology; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects / Q000201:enzymology; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000201:enzymology; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000096:biosynthesis*
D015780:Carbapenems; D002511:Cephalosporins; C060114:SUN 5555; D001618:beta-Lactamases